Bioventus
BVS
84 hedge funds and large institutions have $81.8M invested in Bioventus in 2022 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 22 increasing their positions, 27 reducing their positions, and 32 closing their positions.
0% more call options, than puts
Call options by funds: $12K | Put options by funds: $12K
6.33% less ownership
Funds ownership: 56.91% → 50.59% (-6.3%)
11% less funds holding
Funds holding: 94 → 84 (-10)
19% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 27
25% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 32
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
67% less capital invested
Capital invested by funds: $246M → $81.8M (-$164M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$12.2M |
| 2 |
JIC
Juniper Investment Company
New York
|
+$5.31M |
| 3 |
KLC
Kent Lake Capital
Reno,
Nevada
|
+$3.27M |
| 4 |
JFG
Jefferies Financial Group
New York
|
+$2.46M |
| 5 |
Millennium Management
New York
|
+$745K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
-$8.1M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$6.04M |
| 3 |
TA
Tamarack Advisers
Carlsbad,
California
|
-$5.25M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$4.73M |
| 5 |
EARNEST Partners
Atlanta,
Georgia
|
-$4.33M |
BVS Hedge Fund Activity: Q4 2022 in Review
84 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Bioventus (BVS) for Q4 2022, worth a combined $81.8M — down 67% from $246M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of BVS and 24 opened new positions — a net loss of 8 holders — while 27 trimmed existing stakes and 22 added.
The largest buyer was Nantahala Capital Management, adding an estimated $12.2M. The largest seller was Royce & Associates, cutting an estimated $8.1M.
- 84 institutional investors held Bioventus (BVS) as of Q4 2022, down from 94 in Q3 2022.
- Funds reported $81.8M of Bioventus stock for Q4 2022, down 67% quarter-over-quarter.
- 24 funds opened new Bioventus positions in Q4 2022 and 32 closed out, a net change of -8 holders.
- The largest Bioventus buyer in Q4 2022 was Nantahala Capital Management, an estimated $12.2M added.
- The largest Bioventus seller in Q4 2022 was Royce & Associates, an estimated $8.1M sold.
Based on aggregated 13F filings for Q4 2022.